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Abstract
PURPOSE—Value, defined as outcomes over costs, has been proposed as a measure to evaluate 
prostate cancer (PCa) treatments. We analyzed standardized outcomes and time-driven activity-
based costing (TDABC) for prostate brachytherapy (PBT) to define a value framework.
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METHODS AND MATERIALS—Patients with low-risk PCa treated with low-dose rate PBT 
between 1998 and 2009 were included. Outcomes were recorded according to the International 
Consortium for Health Outcomes Measurement (ICHOM) standard set, which includes acute 
toxicity, patient-reported outcomes, and recurrence and survival outcomes. Patient-level costs to 
one year after PBT were collected using TDABC. Process mapping and radar chart analyses were 
conducted to visualize this value framework.
RESULTS—A total of 238 men were eligible for analysis. Median age was 64 (range, 46–81). 
Median follow-up was 5 years (0.5–12.1). There were no acute grade 3–5 complications. EPIC-50 
scores were favorable, with no clinically significant changes from baseline to last follow-up at 48 
months for urinary incontinence/bother, bowel bother, sexual function, and vitality. Ten-year 
outcomes were favorable, including biochemical failure-free survival of 84.1%, metastasis-free 
survival 99.6%, PCa-specific survival 100%, and overall survival 88.6%. TDABC analysis 
demonstrated low resource utilization for PBT, with 41% and 10% of costs occurring in the 
operating room and with the MRI scan, respectively. The radar chart allowed direct visualization 
of outcomes and costs.
CONCLUSIONS—We successfully created a visual framework to define the value of PBT using 
the ICHOM standard set and TDABC costs. PBT is associated with excellent outcomes and low 
costs. Widespread adoption of this methodology will enable value comparisons across providers, 
institutions, and treatment modalities.
Keywords
Value; Prostate; Brachytherapy; outcomes; time-driven activity-based costing; TDABC
INTRODUCTION
Direct medical costs of cancer care, including costs for localized prostate cancer (PCa) [1], 
have risen dramatically [2, 3] and have nearly doubled between 1987 and 2005, approaching 
nearly $125 billion annually. PCa can be treated with a variety of treatment modalities, 
including active surveillance, brachytherapy (PBT), intensity-modulated radiation therapy 
(IMRT), proton therapy, or radical prostatectomy. Despite the steep rise in cost, there has 
been little evidence of a rise in clinical outcomes [4–6]. In reality, recent studies have shown 
that reimbursement incentives under the current fee-for-service (FFS) system have, in part, 
led to the decreased utilization of cost-effective modalities, such as PBT [6, 7], and 
simultaneous increase in use of more expensive alternatives, such as IMRT [8]. Increasingly, 
payment for cancer care will be moving away from FFS and towards value-based payment 
[9], defined by better outcomes achieved at lower financial cost.
At the core of sub-optimal outcomes and higher costs is a measurement gap, where validated 
and accepted outcome and costing metrics are not systematically collected or reported for 
patients treated for PCa over the full cycle of care. Porter and colleagues have advocated that 
treatments for medical conditions be evaluated by the value they create for patients [10, 11]. 
Providers have been unable to implement the value framework because of inconsistent 
collection and reporting of outcome metrics by medical condition, particularly patient-
reported outcomes (PROs). Providers also do not collect accurate cost data by medical 
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condition across a patient’s care cycle. As a result, providers cannot compare outcomes and 
costs across institution to identify and implement best practices that could increase the value 
of care delivery.
This paucity of valid value-based measurements, however, is changing. The International 
Consortium for Health Outcomes Measurement (ICHOM) [12] has recently defined a 
standardized set of rigorous and multi-dimensional outcome metrics that potentially sets a 
modern standard for all men with localized prostate cancer and holds promise for clinical 
comparisons across the healthcare system.
Historically, studies assessing the cost of various treatment modalities have focused on 
reimbursed costs rather than actual resource utilization throughout the entire cycle of patient 
care. The current FFS system has led to a focus on volume over value [13], cross-
subsidization of under-valued services, and fragmentation of healthcare services with little 
incentive to improve coordination between provider groups [14–16]. Time-driven activity-
based costing (TDABC) has been introduced to health care to remedy these problems [17, 
18]. TDABC is a bottom-up costing tool that measures resource utilization over the full 
cycle of patient care to determine the true cost of delivering care to the provider [19–21]. 
This methodology has been successfully utilized by several industries [17, 18], and more 
recently, TDABC has been used to measure costs and drive process improvements in a 
variety of medical settings [22, 23].
This study is the first to apply the value framework for prostate cancer treatment. We 
implement the ICHOM standard set and TDABC in order to define the standardized value 
framework for low-risk PCa, using PBT as a model example.
MATERIALS AND METHODS
Patient Selection Criteria
Patients with low-risk PCa treated with 125I (98%) or 103Pd (2%) prostate brachytherapy 
monotherapy between May 1998 and November 2009 were eligible for this institutional 
review board-approved analysis. Criteria for low-risk included: 1) pre-treatment prostate-
specific antigen (PSA) ≤ 10 ng/mL; 2) Gleason Score ≤ 6; and 3) American Joint Committee 
on Cancer (AJCC 7th edition) Stage ≤ T2a. Information on tumor stage and grade, initial 
serum PSA level, race, age, medical comorbidities, medications, survival, recurrence, and 
toxicity data were prospectively inputted into an outcome database. PROs were also 
prospectively collected but inputted into a separate outcome database. All patients were 
treated definitively with monotherapeutic PBT and mostly prescribed doses of 144–145 Gy 
using a standard transrectal ultrasound-guided, transperineal technique with preloaded 
brachytherapy needles, as described previously [24, 25]. No patient in this study received 
supplemental external beam radiation therapy or androgen deprivation therapy.
Measurement of patient-centered outcomes
The ICHOM standard set of patient-centered outcomes for localized prostate cancer [12] 
was utilized to measure and report outcomes. These data were prospectively collected by the 
clinical and research staff. Major radiation complications were recorded via the Common 
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Terminology Criteria for Adverse Events (CTCAE), version 4.0 [26] at 6 months after PBT, 
as defined by the ICHOM standard set. Patient-reported health status was recorded via the 
Expanded Prostate Cancer Index Composite (EPIC)-50 questionnaire [27, 28] given before 
initiation of PBT (i.e. baseline) and at regular follow-up intervals of 1, 4, 8, and 12 months 
after brachytherapy and for every 6 months thereafter, as described previously [29]. EPIC 
endpoints for urinary continence, urinary bother, bowel bother, sexual function, and 
hormonal function (vitality) were used at last follow-up to track PRO, as suggested by 
ICHOM. EPIC scores were tabulated according to EPIC instrument guidelines scaled from 0 
to 100, with higher scores representing better outcomes [28]. Biochemical failure (bFFS) 
based upon the Phoenix Consensus Conference PSA elevation definition [30], metastasis-
free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS) 
were recorded for survival and disease control outcome dimensions, as described previously 
[29, 31]. Outcome metrics were obtained from all three outcome tiers, as previously 
described [10, 32].
Statistical Analysis
The Kaplan-Meier product-limit estimator was used to estimate OS and bFFS of patients 
from the date of PBT implant. Cumulative incidence of late grade 2 and 3+ genitourinary 
(GU) toxicity, rectal toxicity, and incidence of biochemical failure were calculated. Death 
was considered a competing event for these estimates. We defined a clinically significant 
change from baseline for an EPIC domain score as 0.5 times the baseline standard deviation 
for that domain, as described previously [33]. Student t-test was utilized to assess if change 
from baseline was significantly different from zero or greater than a clinically significant 
change from baseline. Changes from baseline were also confirmed utilizing a second 
published methodology for determining the minimally important difference for EPIC scores 
[34], but not reported in this manuscript. All statistical analyses were performed using SAS 
9.3 (SAS Institute Inc., Cary, NC), S-PLUS© 7.0 for Windows (Insightful Corp., Seattle, 
Washington), and STATA™ 11.0 for Windows (StataCorp LP, College Station, Texas).
TDABC Measurement
Process Mapping—Process maps were created for the full cycle of PBT from initial 
consultation (Figure 1A) and treatment planning (Figure 1B) to one year after implantation 
and for all ancillary clinical services rendered during the course of RT. All process maps 
were created in 2012. A one year time-point was chosen for costing analysis to capture the 
costs of resource utilization after implantation, but to also limit the analysis to a finite period 
of time that would provide information pertinent to potential future alternative payment 
models. Each step in the process map was associated with a specific personnel resource and 
the time required by that person to perform that activity step [35]. Activity times for each 
activity were documented by content experts, by frontline clinical staff, by direct observation 
of personnel, and from the institutional scheduling system. Decision and chance nodes were 
embedded throughout the process maps, with percentage value at each node to indicate the 
probability that each patient would pass through that specific clinical pathway. A chance 
node occurs when at least two possible outcomes can occur where a degree of uncertainty 
exists. A decision node occurs when a decision between at least two possible alternatives 
could be made.
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Cost Calculation—TDABC analyses were conducted as previously described [35, 36]. 
Briefly, each activity was associated with a personnel resource. Adjusted average hourly 
rates (AHR) were calculated for each personnel resource based upon the particular job code. 
Compensation data based on job codes were obtained from the institutional PeopleSoft 
(Oracle Inc., Redwood Shores, CA) payroll application. Fully allocated costs included 
employment costs, such as salary and benefits, direct costs associated with treatment, and 
indirect costs. The total salary and benefit expense for a particular job group was divided by 
the annual number of work hours in a year, and adjusted for non-productive and indirect 
work time. The AHR was divided by 60 minutes to calculate the dollar per minute capacity 
cost rate (CCR). The cost of performing each activity could then be calculated by 
multiplying the time elapsed during the activity in minutes by the CCR for the personnel 
resource performing the activity. Costs associated with depreciation of radiation therapy and 
diagnostic imaging equipment were also embedded into the cost analysis using a simple 
depreciation model based upon institutional and manufacturer’s recommendations. The total 
TDABC cost for the full cycle of brachytherapy was calculated as the sum of the cost of all 
patient activities from initial consultation to one year after the PBT implant. All costs are 
based upon data from the 2012 fiscal year.
Radar Chart Analysis
We used the radar chart tool in Microsoft Excel (Microsoft Corporation, Redmond, WA) to 
visually display the cost and all outcome metrics in a single diagram [37]. Outcome data 
points for each treatment modality were graphed on separate axes, with all axes being scaled 
equally from 0–100.
RESULTS
Patient demographic and clinical characteristics for all 238 eligible men with low-risk PCa 
are summarized in Table 1. Median age was 64 (range, 46–81) and median follow-up for 
patient centered outcomes was 5 years (range, 0.5–12.1) and TDABC cost was measured up 
to one year after PBT implant.
Acute complications of PBT
There were no CTCAE grade 3, 4, or 5 complications within 6 months of PBT (Table 2). 
The cumulative incidence of grade 2 GU toxicity at 2, 5, and 10 years was 9.2%, 20.7%, and 
23.0%, respectively (Supplemental Figure 1A). However, grade 2 toxicity was reached 
when the patient required an alpha-blocker medication (e.g. tamsulosin) for urinary 
symptoms, regardless of the length of time on the medication. The cumulative incidence of 
late grade 3+ GU toxicity at 2, 5, and 10 years was 1.3%, 1.7%, and 4.9%, respectively 
(Supplemental Figure 1B). The cumulative incidence of grade 2 rectal toxicity at 2, 5, and 
10 years was 2.1%, 3.0%, and 3.0%, respectively (Supplemental Figure 2A). The 
cumulative incidence of late grade 3+ GI toxicity at 2, 5, and 10 years was 0.8% 
(Supplemental Figure 2B).
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Patient-reported health status
Forty-eight month EPIC-50 follow-up data were available for PRO analysis (Table 2). There 
were statistically significant changes from baseline at one and four months for both bowel 
bother (p = 0.018) and urinary bother (p < 0.001) (Figure 2). However, there were no 
changes from baseline for any PRO at any other time point, including the most recent 48-
month follow-up.
Survival and disease control
Ten-year outcome data were used to report survival and disease control outcomes. At last 
follow-up, 5 patients (2%) were alive with disease, 14 (6%) patients were dead without 
evidence of disease, and at least 214 patients (90%) were alive with no evidence of disease. 
PCSS at 10-years was 100%, with all five patients with biochemical failure and one patient 
with metastasis remaining alive at last follow-up. bFFS (based upon an elevated PSA after 
PBT) was 97.5%, 94.2%, and 84.1% at 2, 5, and 10 years, respectively. Survival free from 
PCa metastasis at 10-years was 99.6%. Overall survival was 97.9%, 95.2%, and 88.6% at 2, 
5, and 10 years, respectively (Table 2).
TDABC and Radar Chart analyses
TDABC costs were aggregated over the full cycle of PBT from the time of initial pre-
registration and consultation through 12 months of follow-up after implantation. The overall 
cost to the provider for delivering PBT and one year of follow-up was low. Forty-one percent 
of the total TDABC cost was accrued in the operating room alone, while the single pre-
operative planning MRI, consultation, and treatment planning were 10%, 7.7%, and 7.8% of 
costs, respectively (Figure 3). Each of the outcome metrics and TDABC costing data were 
plotted on a single radar chart diagram (Figure 4).
DISCUSSION
In this study, we successfully applied a standardized outcome metric set developed by 
ICHOM and analyzed costing data with TDABC to develop a framework for communicating 
the value of PCa treatments, using PBT as a model example. Our analysis confirms that PBT 
delivers excellent short-term, patient-reported, and long-term outcomes at low costs to the 
provider.
Value-based healthcare delivery holds promise for aligning the interests of all healthcare 
stakeholders by improving outcomes and decreasing healthcare delivery costs. However, 
outcome measures have traditionally been non-standardized and costing measures have 
rarely been utilized, making meaningful treatment modality comparisons challenging for 
patients. PCa, in particular, can be treated with several highly effective treatment options. 
However, the absence of comparative clinical data and reimbursement incentives under the 
current FFS system have, in part, lead to the decreased utilization of cost-effective 
modalities, such as PBT [7], and the concomitant increase in use of IMRT [6] and urology-
owned IMRT facilities [8]. The lack of randomized and standardized evidence comparing 
PROs between PBT and other options for low-risk PCa also make it difficult for patients and 
providers to make informed treatment decisions [38]. A standard set of outcome-based 
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(included PRO) and costing metrics would help focus the discussion on comparative clinical 
and cost effectiveness of various interventions.
Historically, prospective payment system-exempt cancer centers have been exempt from 
many payment reform and public reporting efforts due to the complexity of cancer care [39]. 
However, Section 3005 of the Patient Protection and Affordable Care Act of 2010 (PPACA) 
specifically establishes a quality-reporting system for these cancer hospitals [40]. Although 
dozens of possible measures have been suggested by various groups, only three cancer-
specific process measures, including the timing of adjuvant chemotherapy in patients with 
AJCC Stage III colon cancer, have been implemented in the program’s first year [41, 42]. In 
order to transition towards a healthcare system that rewards high-value care, focus will need 
to turn to streamlining outcome metric collection to enable comparative outcome and cost 
measurement across a wide range of providers that are customized and specific to the type of 
medical condition being treated. In the case of PCa, functional outcomes, such as 
incontinence and sexual function, are vital measures of the quality of care delivered and are 
important to patient decision-making [14]. Indeed, increased funding for patient-centered 
outcomes research, through the federally-funded Patient-Centered Outcomes Research 
Institute, has placed an emphasis on functional and PROs [43]. The ICHOM standard set 
used in this study is a particularly promising set of outcome metrics that can allow for 
meaningful comparisons across a global network of providers in order to better identify best 
practices and optimize the patient decision-making process [12]. This standard set is a 
product of a cross-disciplinary effort that has focused on literature-derived outcome metrics, 
including PRO.
In addition to outcome measures, the measurement of provider cost is equally important 
when communicating the value of healthcare delivery. A singular focus on improving 
outcomes, even when modest gains are realized, could raise costs inordinately. Conversely, 
in the absence of valid outcome metrics, cost reduction initiatives, even when based on valid 
costing data, could ultimately reduce the quality of care and result in worse outcomes. 
Furthermore, focus on improving a single outcome or cost metric can also lead to 
inadvertent worsening of other, non-measured outcome metrics, highlighting the need for 
collection of a wide-range of metrics. Both outcome and costing measures, therefore, need 
to be simultaneously measured and managed at the individual patient-level (rather than 
simply from a population-level) to ensure that recommended changes will increase, rather 
than decrease, value.
Our current and previous work suggests that TDABC is an innovative costing methodology 
that can be utilized to measure the true cost of care delivery [17, 18, 44, 45]. Traditionally, 
measurement of “costs” in healthcare has relied on summation of reimbursements, which are 
not directly related to the intensity of healthcare resources that are needed to deliver care. 
Reimbursements and coverage of healthcare services, instead, are a result of current and 
historical political, economic, and social pressures [46]. TDABC is uniquely positioned to 
identify the true cost drivers of healthcare delivery and can, therefore, provide insight into 
how to improve the efficiency and quality of healthcare delivery. In our analysis, we 
demonstrate the major cost drivers of PBT over the complete care cycle. The realization that 
the combined cost of the operating room and the MRI scan is more than half of the full care 
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cycle has focused our quality improvement initiatives to improving the efficiency of 
operating room time and making more judicious use of pre-operative MRI scans for low-risk 
PCa patients. These findings have led to eliminating non-value-added steps, driving process 
improvements, sharing best practices across institutions, and even conceptualizing potential 
reimbursement rates in future bundled payment environments. Similar studies for other 
treatment modalities for prostate cancer will lead to an opportunity to improve the efficiency 
and lower the cost of delivering those modalities, enable value comparison across multiple 
modalities, and would inform selection and reimbursement for the alternative modalities. 
However, our TDABC costs in this study reflect the PBT technique utilized at our 
institution, and costs and resource utilization will likely differ between institutions. These 
costs will also change if another isotope, such as 131Cs or 103Pd, are utilized instead of 125I. 
Finally, limiting cost accounting to the first 12 months after PBT may not capture the costs 
associated with managing late toxicities and recurrence. As we continue to accrue more 
longitudinal costing data for PBT and other competing modalities of treatment, we will be 
able to further define the acute and long-term costs associated with each modality and its 
toxicity or recurrence profiles.
Despite the proof-of-principle nature of this study, there are several limitations to expanded 
adoption of this approach. First, the ICHOM standard set includes a wide-range of outcome 
metrics including PROs that may be difficult for some provider organizations to adopt. In 
our institution, we have utilized the expanded EPIC survey over the past 10 years, whereas 
other organizations have historically implemented different surveys, or even no PRO 
measures at all [12]. Given the evolving nature of PRO assessment in healthcare, limited 
cross-walks exist between PRO tools [43, 47], which can create additional barriers for 
comparative analyses. Certain PRO endpoints also have limited usefulness for patients. For 
instance, the ICHOM sexual function metric is currently scored based on the aggregated 
EPIC survey score, but a more meaningful analysis may be to identify the proportion of 
patients who can maintain erections firm enough for sexual activity [48] at follow-up. 
Similarly, cumulative grade 2 GU toxicities are recorded when patients utilize an alpha-
blocker medication for even a transient period of time – an endpoint that may not be 
meaningful to patients’ long-term outcomes. Although the ICHOM set includes a wide-
range of outcomes, it does not include other meaningful metrics, such as time to recovery, 
access to care, emergency room and hospital visits, and others. The standard set also intends 
for mean or median EPIC values as endpoints, rather than proportion of patients 
experiencing a minimally important difference, which would potentially be more 
informative and consistent with other reported parameters. Furthermore, our analysis 
incorporated outcomes from patients treated over an 11 year period, while a more recent 
time period was utilized to generate the TDABC cost. Additionally, although other 
modalities, such as active surveillance, may become preferred choices for management for 
the low risk prostate cancer patient group, the principles and methodology utilized in this 
manuscript can readily be applied to other treatments, other risk groups, and even other 
disease sites in the future. Given these limitations, this value framework necessarily utilizes 
a snapshot of several outcome and costing metrics, but we anticipate that this framework 
will need to continually evolve and be updated as new data on metrics become available.
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Furthermore, as healthcare organizations move towards value measurement, providers will 
need to increasingly utilize health information technology to seamlessly gather and report 
outcome and cost data. Unfortunately, most electronic medical records (EMR) do not 
uniformly capture the three tiers of outcomes described in this study, which places additional 
pressure on provider staff to manually maintain and abstract data from research databases or 
EMRs. In this study of PBT alone, our research staff needed to manually abstract data from 
two prospectively-maintained databases to collect the full range of outcome metrics. 
TDABC costing analyses also required manual calculation as well as time-intensive 
collaboration with financial teams. These TDABC analyses are also specific to each 
institution, and data collection, therefore, require substantial time and resources from each 
provider. Current efforts are underway in our institution to compare PBT with other 
treatment modalities, but such large-scale comparisons have required an even larger manual 
effort to abstract data, as described previously [49].
CONCLUSION
Measuring and publicly reporting a standard set of clinical outcomes and costs will provide 
a more rigorous approach to understanding the value of treatments and will galvanize value-
based competition among provider organizations. In this study, we demonstrate successful 
implementation of a novel value framework using PBT as a model. Efforts are currently 
underway to utilize these measurement tools to compare the value of PCa care among 
providers within a single institution, among providers across regional care centers, among 
providers in different institutions, and among various treatment modalities. Future payment 
reform will tie reimbursement to the demonstrable value of care, and we will therefore need 
to develop a focused infrastructure to collect, analyze, and report outcome and costing 
metrics to assign value accurately.
List of abbreviations
PCa prostate cancer
TDABC time-driven activity-based costing
PBT prostate brachytherapy
ICHOM International Consortium for Health Outcomes Measurement
EPIC Expanded Prostate Cancer Index Composite
MRI magnetic resonance imaging
FFS fee-for-service
IMRT intensity-modulated radiation therapy
PROs patient-reported outcomes
PSA prostate-specific antigen
CTCAE Common Terminology Criteria for Adverse Events
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bFFS Biochemical failure free survival
MFS metastasis-free survival
PCSS prostate cancer-specific survival
OS overall survival
GU genitourinary
AHR Adjusted average hourly rates
CCR capacity cost rate
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Figure 1. 
Example process maps for brachytherapy. (A) Consultation; (B) Treatment planning. Each 
box represents a step or activity through which a patient passes in the process. The number 
at top of each box represents the number in sequence of step/activity. Colors in each box 
represent the resource that completes the step/activity in the process. Numbers circled at 
bottom right corner of step/activity box are used to represent the estimated number of 
minutes needed to complete each activity described in the box. In this example, the minutes 
are simply used as examples and do not reflect true process times. Percentages are the 
probability that patients pass through each step in the process, Y = yes, N = no. MD, 
radiation oncology physician.
Thaker et al. Page 13
Brachytherapy. Author manuscript; available in PMC 2017 July 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
EPIC score change from baseline. There were statistically significant changes from baseline 
at 1 and 4 months for both bowel bother and urinary bother. However, there were no changes 
from baseline for any PRO at any other time point, including the most recent 48-month score
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Figure 3. 
Time-driven activity-based costing (TDABC) of PBT from initial preregistration and 
consultation through one-year follow-up after PBT implantation.
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Figure 4. 
Radar Chart representing the value framework for PBT. The radar chart tool can be used to 
visualize multiple outcome and costing metrics simultaneously. The chart allows direct 
visualization of the 6-month complications, 4-year patient reported outcomes, 10-year 
survival, and TDABC provider costs at one year after implantation. The red line visually 
connects each numerical outcome or cost value on each axis. The blue dotted line represents 
the baseline EPIC scores prior to PBT treatment.
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Table 1
Patient demographics and treatment characteristics. ANED, alive without evidence of disease. AWD, alive 
with disease. DNED, dead without evidence of disease. NED, without evidence of disease.
Characteristic Value
Total number of patients 238
Median follow-up (range) 5 (0.5–12.1) yrs
Median age (range) 64 (46–81) yrs
Race (%)
 White 211 (89)
 Black 17 (7)
 Hispanic 6 (3)
 Asian 3 (1)
 Other 1 (0)
AJCC Stage (%)
 T1c 192 (81)
 T2a 46 (19)
Gleason Score (%)
 5 1 (1)
 6 237 (99)
Mean PSA (range) 5.1 (0.6–9.8) ng/mL
Implant Type (%)
 I-125 236 (99)
 Pd-103 2 (1)
Implant Dose (Gy) (%)
 145 208 (87)
 144 28 (12)
 125 2 (1)
Hypertension (%)
 No 124 (52)
 Yes 111 (47)
 Unknown 3 (1)
Diabetes (%)
 No 212 (89)
 Yes 22 (9)
 Unknown 4 (2)
Vascular Disease (%)
 No 195 (82)
 Yes 40 (17)
 Unknown 3 (1)
Prior Rectal Surgery (%)
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Characteristic Value
 No 227 (95)
 Yes 2 (1)
 Unknown 9 (4)
History of Hemorrhoids (%)
 No 181 (76)
 Yes 47 (20)
 Unknown 10 (4)
Anticoagulant Use (%)
 No 170 (71)
 Yes 65 (27)
 Unknown 3 (1)
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Table 2
Standardized PBT outcomes.
Acute Complications 6 months (CTCAE grade 3 or 4)
 Major surgical complications 0%
 Major radiation complications 0%
Patient-reported outcomes 4-year EPIC Outcomes
Baseline Outcome P-value
 Urinary Continence 92.7 88.3 NS
 Urinary Bother 87.4 88.7 NS
 Bowel Bother 96 94.5 NS
 Sexual Function 53.9 48 NS
 Vitality 91.2 91.1 NS
Survival and disease control 10-year outcomes
 Biochemical failure-free survival 84.1%
 Metastasis-free survival 99.6%
 Prostate cancer-specific survival 100%
 Overall survival 88.6%
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